Dominick Colangelo
Directeur Général chez VERICEL CORPORATION
Fortune : 10 M $ au 30/04/2024
Postes actifs de Dominick Colangelo
Sociétés | Poste | Début | Fin |
---|---|---|---|
VERICEL CORPORATION | Directeur/Membre du Conseil | 01/03/2013 | - |
Directeur Général | 01/03/2013 | - | |
President | 01/03/2013 | - | |
TREVI THERAPEUTICS, INC. | Directeur/Membre du Conseil | 29/06/2020 | - |
Independent Dir/Board Member | 29/06/2020 | - |
Historique de carrière de Dominick Colangelo
Anciens postes connus de Dominick Colangelo
Sociétés | Poste | Début | Fin |
---|---|---|---|
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Directeur/Membre du Conseil | 23/02/2011 | 15/05/2012 |
Directeur Général | 01/12/2008 | 15/05/2012 | |
President | 01/12/2008 | 15/05/2012 | |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Directeur des opérations | 01/01/2005 | 11/12/2008 |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Directeur en chef des Investissements | - | 07/12/2005 |
Private Equity Investor | - | 07/12/2005 | |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/1995 | - |
Formation de Dominick Colangelo
State University of New York at Buffalo | Undergraduate Degree |
Duke University School of Law | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Opérationnelle
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 2 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
VERICEL CORPORATION | Health Technology |
TREVI THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
- Bourse
- Insiders
- Dominick Colangelo
- Expérience